144 related articles for article (PubMed ID: 37333166)
1. Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review.
Wallace G; Kundalia R; Cao B; Kim Y; Smalley I; Forsyth P; Soyano A; Pina Y
Res Sq; 2023 Jun; ():. PubMed ID: 37333166
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
3. Leptomeningeal disease and breast cancer: the importance of tumor subtype.
Abouharb S; Ensor J; Loghin ME; Katz R; Moulder SL; Esteva FJ; Smith B; Valero V; Hortobagyi GN; Melhem-Bertrandt A
Breast Cancer Res Treat; 2014 Aug; 146(3):477-86. PubMed ID: 25038877
[TBL] [Abstract][Full Text] [Related]
4. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
5. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis.
Yust-Katz S; Garciarena P; Liu D; Yuan Y; Ibrahim N; Yerushalmi R; Penas-Prado M; Groves MD
J Neurooncol; 2013 Sep; 114(2):229-35. PubMed ID: 23756727
[TBL] [Abstract][Full Text] [Related]
8. The shifting landscape of metastatic breast cancer to the CNS.
Quigley MR; Fukui O; Chew B; Bhatia S; Karlovits S
Neurosurg Rev; 2013 Jul; 36(3):377-82. PubMed ID: 23262837
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
Figura NB; Rizk VT; Mohammadi H; Evernden B; Mokhtari S; Yu HM; Robinson TJ; Etame AB; Tran ND; Liu J; Washington I; Diaz R; Czerniecki BJ; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2019 Jun; 175(3):781-788. PubMed ID: 30859348
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for leptomeningeal disease in breast cancer.
Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
[TBL] [Abstract][Full Text] [Related]
12. Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.
Kim HK; Lee HS; Heo MH; Kim JY; Ahn JS; Im YH; Lee JI; Park YH
Clin Breast Cancer; 2021 Aug; 21(4):e402-e414. PubMed ID: 33526378
[TBL] [Abstract][Full Text] [Related]
13. Identification of risk factors associated with leptomeningeal disease after resection of brain metastases.
Morshed RA; Saggi S; Cummins DD; Molinaro AM; Young JS; Viner JA; Villanueva-Meyer JE; Goldschmidt E; Boreta L; Braunstein SE; Chang EF; McDermott MW; Berger MS; Theodosopoulos PV; Hervey-Jumper SL; Aghi MK; Daras M
J Neurosurg; 2023 Aug; 139(2):402-413. PubMed ID: 36640095
[TBL] [Abstract][Full Text] [Related]
14. Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer.
Trifiletti DM; Romano KD; Xu Z; Reardon KA; Sheehan J
J Neurooncol; 2015 Sep; 124(3):421-7. PubMed ID: 26093620
[TBL] [Abstract][Full Text] [Related]
15. Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
Id Said B; Soliman H; Moravan V; Myrehaug S; Tseng CL; Detsky J; Sahgal A; Warner E; Jerzak KJ
J Neurooncol; 2023 Sep; 164(2):437-445. PubMed ID: 37634217
[TBL] [Abstract][Full Text] [Related]
16. Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702).
Aoyagi K; Higuchi Y; Matsunaga S; Serizawa T; Yomo S; Aiyama H; Nagano O; Kondoh T; Kenai H; Shuto T; Kawagishi J; Jokura H; Sato S; Nakazaki K; Nakaya K; Hasegawa T; Kawashima M; Kawai H; Yamanaka K; Nagatomo Y; Yamamoto M; Sato Y; Aoyagi T; Matsutani T; Iwadate Y
Breast Cancer Res Treat; 2020 Nov; 184(1):149-159. PubMed ID: 32737714
[TBL] [Abstract][Full Text] [Related]
17. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
[TBL] [Abstract][Full Text] [Related]
18. Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer.
Haque W; Verma V; Adeberg S; Rustomily R; Lo S; Butler EB; Teh BS
Rep Pract Oncol Radiother; 2021; 26(3):341-351. PubMed ID: 34277087
[TBL] [Abstract][Full Text] [Related]
19. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
20. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
Gao C; Wang F; Suki D; Strom E; Li J; Sawaya R; Hsu L; Raghavendra A; Tripathy D; Ibrahim NK
Int J Cancer; 2021 Feb; 148(4):961-970. PubMed ID: 32748402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
